POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
Public ClinicalTrials.gov record NCT05953688. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Proof-of-Concept, Randomized, Double-Masked Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Noninfectious Intermediate, Posterior, or Panuveitis (OPTYK-1)
Study identification
- NCT ID
- NCT05953688
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Alumis Inc
- Industry
- Enrollment
- 36 participants
Conditions and interventions
Interventions
- ESK-001 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 13, 2023
- Primary completion
- Aug 12, 2024
- Completion
- Aug 12, 2024
- Last update posted
- Aug 27, 2024
2023 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site#1065 | Beverly Hills | California | 90211 | — |
| Investigator Site #1073 | Los Angeles | California | 90033 | — |
| Investigator Site #1072 | Los Angeles | California | 90095 | — |
| Investigator Site #1080 | Palo Alto | California | 94303 | — |
| Investigator Site #1079 | Sacramento | California | 95825 | — |
| Investigator Site#1068 | Lakewood | Colorado | 80228 | — |
| Investigator Site #1086 | Oak Park | Illinois | 60304 | — |
| Investigator Site #1085 | Hagerstown | Maryland | 21740 | — |
| Investigator Site #1069 | Waltham | Massachusetts | 02451 | — |
| Investigator Site #1076 | Palisades Park | New Jersey | 07650 | — |
| Investigator Site #1083 | Durham | North Carolina | 27705 | — |
| Investigator Site #1064 | Erie | Pennsylvania | 16507 | — |
| Investigator Site#1066 | Nashville | Tennessee | 37203 | — |
| Investigator Site #1084 | Nashville | Tennessee | 37232 | — |
| Investigator Site#1075 | Bellaire | Texas | 77401 | — |
| Investigator Site #1074 | Katy | Texas | 77494 | — |
| Investigator Site #1078 | Plano | Texas | 75075 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05953688, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05953688 live on ClinicalTrials.gov.